Mofebutazone

Mofebutazone

Clinical data
ATC code	M01AA02 (WHO) M02AA02 (WHO)
Identifiers
IUPAC name 4-butyl-1-phenylpyrazolidine-3,5-dione
CAS Number	2210-63-1^Y
PubChem CID	16639
ChemSpider	15776^N
UNII	SPW36WUI5Z
KEGG	D07262^Y
ChEBI	CHEBI:76252^N
CompTox Dashboard (EPA)	DTXSID4023331
ECHA InfoCard	100.016.947
Chemical and physical data
Formula	C13H16N2O2
Molar mass	232.283 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCCC1C(=O)NN(C1=O)c2ccccc2
InChI InChI=1S/C13H16N2O2/c1-2-3-9-11-12(16)14-15(13(11)17)10-7-5-4-6-8-10/h4-8,11H,2-3,9H2,1H3,(H,14,16)^N Key:REOJLIXKJWXUGB-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

Mofebutazone (or monophenylbutazone) is a drug used for joint and muscular pain.^[1][2] It is a 3,5-pyrazolinedione derivative.

The drug binds to plasma albumin and competes with drugs such as coumarin anticoagulants, indomethacin and glucocorticoids.

References

1. Kassem MA, Schulte KE (1984-07-01). "Pharmacokinetics of [4-14C] mofebutazone after oral administration in man". European Journal of Drug Metabolism and Pharmacokinetics. 9 (3): 223–227. doi:10.1007/BF03189645. PMID 6519123. S2CID 10985688.
2. Paradies HH (December 1987). "Structure of phenylbutazone and mofebutazone in the crystalline state and in solution". Journal of Pharmaceutical Sciences. 76 (12): 920–929. doi:10.1002/jps.2600761217. PMID 3440938.